High serum levels of type I (IFNα), II (IFNγ), and III (IFNλ1) are observed in patients with SLE and have been associated with high disease activity; thus, IFNs are considered to be key molecules in the pathogenesis of SLE (71–74). This evidence concerns the gene IFNA1 and systemic lupus erythematosus.